Research graph
References from Lipoprotein(a) and residual risk during statin therapy: thresholds guide decisions, but risk is continuous. Local targets link to admitted publications; unresolved targets remain external evidence.
Lipoprotein(a)
10.1001/jama.2025.2373 · 2025 · External reference
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
10.1093/eurheartj/ehac361 · 2022 · External reference
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
10.1093/eurheartj/ehaf190 · 2025 · External reference
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.11.016 · 2026 · External reference
Lp(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank
10.1161/atvbaha.120.315291 · 2021 · External reference
Lipoprotein(a) and residual cardiovascular risk in statin-treated patients: a UK biobank analysis
2026 · External reference
Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis
10.1161/circulationaha.124.069556 · 2025 · External reference
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
10.1161/circulationaha.113.004406 · 2014 · External reference
Lipoprotein(a) levels, risk of cardiovascular events, and benefit of evolocumab: findings from the VESALIUS-CV trial
10.1161/circulationaha.126.080999 · 2026 · External reference
Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease
10.1016/j.jacc.2023.12.031 · 2024 · External reference
